Recruiting A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) NCT07188896 Conditions Adenocarcinoma, Advanced Renal Cell Carcinoma (aRCC), Carcinoma, +16 more Locations Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin, United States View Trial Details
Not Yet Recruiting Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma NCT07159191 Conditions Advanced Renal Cell Carcinoma (aRCC) Locations Not specified View Trial Details
Completed Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients NCT06345183 Conditions Advanced Renal Cell Carcinoma (aRCC) Locations Cardinal Health — Dublin, Ohio, United States View Trial Details
Completed Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination NCT04957160 Conditions Advanced Renal Cell Carcinoma (aRCC) Locations Beatson West of Scotland Cancer Centre — Glasgow, United Kingdom Royal Surrey County Hospital — Guildford, United Kingdom Barts Cancer Institute — London, United Kingdom Royal Marsden Hospital — London, United Kingdom View more locations Show fewer locations Loading locations... View Trial Details
